These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 1458660)

  • 1. Loceryl nail lacquer--realization of a new galenical approach to onychomycosis therapy.
    Pittrof F; Gerhards J; Erni W; Klecak G
    Clin Exp Dermatol; 1992 Sep; 17 Suppl 1():26-8. PubMed ID: 1458660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
    Monti D; Saccomani L; Chetoni P; Burgalassi S; Senesi S; Ghelardi E; Mailland F
    Br J Dermatol; 2010 Feb; 162(2):311-7. PubMed ID: 19886884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly.
    Reinel D; Clarke C
    Clin Exp Dermatol; 1992 Sep; 17 Suppl 1():44-9. PubMed ID: 1458665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis.
    Schaller M; Sigurgeirsson B; Sarkany M
    Mycoses; 2017 Dec; 60(12):800-807. PubMed ID: 28925059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of 5% amorolfine nail lacquer in Neoscytalidium dimidiatum onychomycosis.
    Bunyaratavej S; Leeyaphan C; Rujitharanawong C; Surawan TM; Muanprasat C; Matthapan L
    J Dermatolog Treat; 2016 Aug; 27(4):359-63. PubMed ID: 26471716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review.
    Feng X; Xiong X; Ran Y
    Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28097731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visualisation of penetration of topical antifungal drug substances through mycosis-infected nails by matrix-assisted laser desorption ionisation mass spectrometry imaging.
    Endringer Pinto F; Bagger C; Kunze G; Joly-Tonetti N; Thénot JP; Osman-Ponchet H; Janfelt C
    Mycoses; 2020 Aug; 63(8):869-875. PubMed ID: 32406142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot, layerwise, ex vivo evaluation of the antifungal efficacy of amorolfine 5% nail lacquer vs other topical antifungal nail formulations in healthy toenails.
    Ghannoum M; Long L; Kunze G; Sarkany M; Osman-Ponchet H
    Mycoses; 2019 Jun; 62(6):494-501. PubMed ID: 30667544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the subungual antifungal activity of amorolfine after 1 month's treatment in patients with onychomycosis: comparison of two nail lacquer formulations.
    Mensing H; Polak-Wyss A; Splanemann V
    Clin Exp Dermatol; 1992 Sep; 17 Suppl 1():29-32. PubMed ID: 1458661
    [No Abstract]   [Full Text] [Related]  

  • 10. Application of cosmetic nail varnish does not affect the antifungal efficacy of amorolfine 5% nail lacquer in the treatment of distal subungual toenail onychomycosis: results of a randomised active-controlled study and in vitro assays.
    Sigurgeirsson B; Ghannoum MA; Osman-Ponchet H; Kerrouche N; Sidou F
    Mycoses; 2016 May; 59(5):319-26. PubMed ID: 26867498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use.
    Reinel D
    Dermatology; 1992; 184 Suppl 1():21-4. PubMed ID: 1532336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
    Paul C; Coustou D; Lahfa M; Bulai-Livideanu C; Doss N; Mokthar I; Turki H; Nouira R; Fazaa B; Ben Osman A; Zourabichvili O; Cazeau C; Coubetergues H; Picot S; Bienvenu AL; Voisard JJ
    Dermatology; 2013; 227(2):157-64. PubMed ID: 24051622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized Ciclopirox-Based Eudragit RLPO Nail Lacquer: Effect of Endopeptidase Enzyme as Permeation Enhancer on Transungual Drug Delivery and Efficiency Against Onychomycosis.
    Khattab A; Shalaby S
    AAPS PharmSciTech; 2018 Apr; 19(3):1048-1060. PubMed ID: 29138987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scytalidium hyalinum onychomycosis successfully treated with 5% amorolfine nail lacquer.
    Downs AM; Lear JT; Archer CB
    Br J Dermatol; 1999 Mar; 140(3):555. PubMed ID: 10233295
    [No Abstract]   [Full Text] [Related]  

  • 15. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement.
    Baran R; Sigurgeirsson B; de Berker D; Kaufmann R; Lecha M; Faergemann J; Kerrouche N; Sidou F
    Br J Dermatol; 2007 Jul; 157(1):149-57. PubMed ID: 17553051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of topical resin lacquer, amorolfine and oral terbinafine for treating toenail onychomycosis: a prospective, randomized, controlled, investigator-blinded, parallel-group clinical trial.
    Auvinen T; Tiihonen R; Soini M; Wangel M; Sipponen A; Jokinen JJ
    Br J Dermatol; 2015 Oct; 173(4):940-8. PubMed ID: 26036329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
    Bohn M; Kraemer KT
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transungual delivery of ketoconazole using novel lacquer formulation.
    Hafeez F; Hui X; Chiang A; Hornby S; Maibach H
    Int J Pharm; 2013 Nov; 456(2):357-61. PubMed ID: 24029171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of topical antifungal products in an in vitro onychomycosis model.
    Sleven R; Lanckacker E; Delputte P; Maes L; Cos P
    Mycoses; 2016 May; 59(5):327-30. PubMed ID: 26857689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of ciclopirox nail lacquer with enhanced permeation and retention.
    Thapa RK; Choi JY; Go TG; Kang MH; Han SD; Jun JH; Son MW; Yong CS; Kim JO
    Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.